Ironwood Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 113.74 million compared to USD 108.64 million a year ago. Net income was USD 15.32 million compared to USD 50.32 million a year ago. Basic earnings per share from continuing operations was USD 0.1 compared to USD 0.33 a year ago. Diluted earnings per share from continuing operations was USD 0.09 compared to USD 0.28 a year ago.
For the nine months, revenue was USD 325.18 million compared to USD 303.4 million a year ago. Net loss was USD 1,001.15 million compared to net income of USD 126.2 million a year ago. Basic loss per share from continuing operations was USD 6.45 compared to basic earnings per share from continuing operations of USD 0.82 a year ago. Diluted loss per share from continuing operations was USD 6.45 compared to diluted earnings per share from continuing operations of USD 0.69 a year ago.